2018

  • ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results

    January 29, 2018

    ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC Houston, TX, USA, January 29, 2018 / B3C newswire / -- ZZ Biotech today announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles. The placebo-controlled dose-escalation trial was designed to establish a maximally tolerated dose (MTD) of 3K3A-APC in patients with acute ischemic stroke treated with intravenous tPA, intra-arterial thrombectomy, or both. A secondary endpoint was to

    Read More